C21 Investments Inc.

CWLXF ·Healthcare, Drug Manufacturers - General
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents — — — — — $6.2M $3.1M $9.1M
Accounts Receivable $57.1K $124.8K $238.0K $401.5K $198.5K $101.2K $443.1K $80.0K
Inventory $4.6M $4.1M $2.9M $4.2M $4.1M $2.7M $6.2M $6.9M
Total Current Assets $8.3M $7.5M $8.1M $8.6M $10.3M $11.3M $11.7M $18.5M
Property, Plant & Equipment $2.3M $2.7M $3.4M $4.7M $4.9M $2.7M — —
Goodwill $28.5M $28.5M $28.5M $28.5M $28.5M $28.5M $28.5M $29.2M
Intangible Assets (Excl. Goodwill) $6.4M $8.1M $6.3M $7.9M $9.2M $11.0M — —
Total Assets $54.4M $57.0M $55.2M $58.3M $61.8M $66.8M $61.5M $77.4M
Liabilities
Accounts Payable $1.3M $1.0M $1.5M $1.8M $1.4M $1.4M $3.5M $5.0M
Total Current Liabilities $6.4M $8.0M $15.0M $15.0M $16.0M $15.2M $38.6M $31.8M
Long-Term Debt — — — — — $462.3K $494.2K —
Total Liabilities $29.0M $28.3M $24.3M $24.0M $28.1M $43.6M $47.8M $56.3M
Stockholders' Equity
Retained Earnings $-80.1M $-76.8M $-72.9M $-69.5M $-69.8M $-79.4M $-70.5M $-38.0M
Total Stockholders' Equity $25.4M $28.7M $31.0M $34.3M $33.7M $23.3M $13.6M $21.1M
← Newer Page 1 of 2 Older →